Literature DB >> 16034368

Cancer/testis antigens, gametogenesis and cancer.

Andrew J G Simpson1, Otavia L Caballero, Achim Jungbluth, Yao-Tseng Chen, Lloyd J Old.   

Abstract

Cancer/testis (CT) antigens, of which more than 40 have now been identified, are encoded by genes that are normally expressed only in the human germ line, but are also expressed in various tumour types, including melanoma, and carcinomas of the bladder, lung and liver. These immunogenic proteins are being vigorously pursued as targets for therapeutic cancer vaccines. CT antigens are also being evaluated for their role in oncogenesis--recapitulation of portions of the germline gene-expression programme might contribute characteristic features to the neoplastic phenotype, including immortality, invasiveness, immune evasion, hypomethylation and metastatic capacity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034368     DOI: 10.1038/nrc1669

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  655 in total

1.  Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instability.

Authors:  Katrine B V Greve; Jonas N Lindgreen; Mikkel G Terp; Christina B Pedersen; Steffen Schmidt; Jan Mollenhauer; Stine B Kristensen; Rikke S Andersen; Mette M Relster; Henrik J Ditzel; Morten F Gjerstorff
Journal:  Mol Oncol       Date:  2014-10-06       Impact factor: 6.603

2.  Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1.

Authors:  Neehar Bhatia; Bing Yang; Tony Z Xiao; Noel Peters; Michael F Hoffmann; B Jack Longley
Journal:  Arch Biochem Biophys       Date:  2011-01-28       Impact factor: 4.013

Review 3.  Raising the bar: the curative potential of human cancer immunotherapy.

Authors:  Steven A Rosenberg
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

Review 4.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

5.  Novel drugs for the treatment of multiple myeloma.

Authors:  Joan Bladé; Ma Teresa Cibeira; Laura Rosiñol
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

6.  CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.

Authors:  Andrew McLarnon; Karen P Piper; Oliver C Goodyear; Julie M Arrazi; Premini Mahendra; Mark Cook; Fiona Clark; Guy Pratt; Charles Craddock; Paul A H Moss
Journal:  Haematologica       Date:  2010-05-11       Impact factor: 9.941

7.  Targets and dynamics of promoter DNA methylation during early mouse development.

Authors:  Julie Borgel; Sylvain Guibert; Yufeng Li; Hatsune Chiba; Dirk Schübeler; Hiroyuki Sasaki; Thierry Forné; Michael Weber
Journal:  Nat Genet       Date:  2010-11-07       Impact factor: 38.330

8.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

Review 9.  Drosophila melanogaster: a model and a tool to investigate malignancy and identify new therapeutics.

Authors:  Cayetano Gonzalez
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

10.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.